| Market Capitalization (Millions $) |
3,448 |
| Shares
Outstanding (Millions) |
116 |
| Employees |
53 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-535 |
| Cash Flow (TTM) (Millions $) |
84 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for serious and life-threatening diseases. The company is headquartered in San Diego, California, and was founded in 201 Viking's goal is to develop innovative therapies that will improve the lives of patients suffering from metabolic and endocrine disorders, as well as other serious diseases.
The company's main focus is on the development of selective and orally available small molecule drugs that mimic the beneficial effects of naturally occurring hormones. The company's lead product candidate is VK5211, a novel treatment for muscle wasting and bone loss. This compound has shown promising results in early clinical trials and may have the potential to help patients with a range of debilitating conditions, including hip fracture recovery, cancer cachexia, and sarcopenia.
Viking's pipeline also includes VK2809, a thyroid beta receptor agonist designed to treat hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD). Other pipeline candidates include VK0214, a thyroid beta receptor agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD), and VK0612, a second-generation thyroid beta receptor agonist for NAFLD and other metabolic disorders.
Viking Therapeutics has a unique research approach that leverages the best of both natural and synthetic compounds. The company's team of experienced scientists uses a combination of high-throughput screening, medicinal chemistry, and pharmacology to identify and optimize drug candidates. Viking has also established strategic partnerships with leading academic institutions and research organizations to accelerate the development and commercialization of their products.
In summary, Viking Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for serious and life-threatening diseases. The company's main focus is on the development of small molecule drugs that mimic the beneficial effects of naturally occurring hormones. Viking's pipeline includes products for muscle wasting, bone loss, hypercholesterolemia, NAFLD, and X-ALD. The company's research approach leverages the best of both natural and synthetic compounds, and the company has established strategic partnerships with leading academic institutions and research organizations to accelerate the development of their products.
Company Address: 9920 Pacific Heights Blvd San Diego 92121 CA
Company Phone Number: 704-4660 Stock Exchange / Ticker: NASDAQ VKTX
|
11.46% 